CASI Pharmaceuticals (CASIF) Receivables (2021 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Receivables came in at $4.1 million in Q4 2025, down 73.33% YoY from $15.3 million in Q4 2024, and up 56.84% on a QoQ basis from $2.6 million in Q3 2025.
CASI Pharmaceuticals (CASIF) Receivables (2021 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 5 years of Receivables data on file, last reported at $4.1 million in Q4 2025.
- Quarterly Receivables fell 73.33% year-over-year to $4.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.1 million (down 73.33% YoY) and the FY2025 annual result came in at $4.1 million, down 72.27% from the prior year.
- Receivables climbed to $4.1 million in Q4 2025, from $2.6 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $12.5 billion in Q2 2023 to a low of $2.6 million in Q3 2025.
- A 5-year average of $3.3 billion and a median of $13.0 million in 2022 frame the typical range for Receivables.
- The widest YoY moves for Receivables: up 125188.49% in 2025, down 99.92% in 2025.
- Tracing CASIF's Receivables over 5 years: stood at $10.0 million in 2021, then surged by 30.97% to $13.0 million in 2022, then soared by 73183.2% to $9.6 billion in 2023, then slumped by 99.84% to $15.3 million in 2024, then plunged by 73.33% to $4.1 million in 2025.
- The last three Receivables figures came in at $4.1 million (Q4 2025), $2.6 million (Q3 2025), and $5.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.09 Mn |
| Sep 30, 2025 | 2.61 Mn |
| Jun 30, 2025 | 5.36 Mn |
| Mar 31, 2025 | 7.60 Bn |
| Dec 31, 2024 | 15.35 Mn |
| Jun 30, 2024 | 6.78 Bn |
| Mar 31, 2024 | 6.07 Mn |
| Dec 31, 2023 | 9.55 Bn |
| Jun 30, 2023 | 12.53 Bn |
| Dec 31, 2022 | 13.03 Mn |
| Dec 31, 2021 | 9.95 Mn |